Skip to content
About
Team
Portfolio
News
Contact
News
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
2024-03-04
Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE2016, a First-in-Class Allogeneic Anti-EGFR Cell Therapy
2024-02-04
Anbogen Secures $12.5 Million USD in Series A Funding, Advancing Precision Oncology Drug Development
2024-02-01
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
2024-01-03
Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation
2023-12-04
Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)
2023-11-28
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer
2023-11-16
ARTHROSI TO PRESENT POSITIVE PHASE 2 DATA FOR ITS NOVEL SELECTIVE URAT1 INHIBITOR AR882 IN PATIENTS WITH TOPHACEOUS GOUT AT ACR CONVERGENCE 2023
2023-11-07
Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation
2023-10-31
Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion
2023-10-26
Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%
2023-10-23
Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023
2023-10-16
Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
2023-09-06
Arthrosi Therapeutics AR882 Prepares to Enter into Global Phase 3 Study
2023-08-18
ARTHROSI SECURES $75M IN SERIES D FINANCING
2023-07-11
Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R. Bryan Miller Symposium
2023-04-11
Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq
2023-03-30
ARTHROSI ANNOUNCES POSITIVE TOPLINE RESULTS FOR AR882 PHASE 2B STUDY
2023-01-05
Apollomics Inc. Receives FDA Orphan Drug Designation for Vebreltinib (APL-101) for Treatment of Non-Small Cell Lung Cancer with MET Genomic Tumor Aberrations
2022-11-15
Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination
2022-10-14
Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business Combination
2022-10-07
Apollomics Inc., a Late-Stage Clinical Biopharmaceutical Company to be Listed on Nasdaq Through Business Combination with Maxpro Capital Acquisition Corp.
2022-09-14
Arthrosi completes AR882 phase 2B study enrollment
2022-08-23
Acepodia Raises $109 Million Series C Financing to Advance Development of First-in-Class Antibody Cell Effector Therapies
2021-12-02
Maxpro Capital Acquisition Corp. Announces the Separate Trading of Its Class A Common Stock and Warrants
2021-11-26
ACT Genomics joins force with Sanomics
2021-11-22
SyneuRx Announces Oral COVID-19 Twindemic Antiviral Drug Candidate Pentarlandir Has Entered Final Portion of FDA Phase II Testing
2021-11-19
Acepodia Strengthens Board of Directors and Scientific Advisory Board with Key Appointments
2021-11-03
Arthrosi Presents AR882 Posters at ACR 2021
2021-11-02
EIRGENIX COMPLETED ITS NTD 5.03 BILLION PRIVATE PLACEMENT ON THE FIFTEENTH OF OCTOBER
2021-10-15
Maxpro Capital Acquisition Corp. Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option
2021-10-13
Arthrosi Appoints Robert Thomas Keenan MD, MPH, MBA as Chief Medical Officer
2021-10-12
Maxpro Capital Acquisition Corp. Announces Pricing of $90,000,000 Initial Public Offering
2021-10-07
CerbACT Asia Holds Ribbon Cutting to Celebrate New Immuno-oncology Centre of Excellence
2021-10-07
Acepodia Presents Positive Interim Phase 1 Feasibility Data for Antibody Cell Effector Therapy, ACE1702, in Advanced HER2-Positive Tumors
2021-09-16
Acepodia to Present Data from Preclinical and Phase 1 Studies of ACE1702 at the European Society for Medical Oncology (ESMO) 2021 Virtual Congress
2021-09-13
Cerba Research and ACT Genomics announce strategic Joint Venture – CerbACT Asia
2021-08-25
Arthrosi Establishes Joint Venture in China to Accelerate Development of Innovative Drug Portfolio
2021-08-17
SPAC Jade Mountain Acquisition files for a $100 million IPO, targeting health and tech
2021-07-22
EIRGENIX ACHIEVES THE FOURTH MILESTONE OF ITS TRASTUZUMAB BIOSIMILAR LICENSING AGREEMENT
2021-07-21
EIRGENIX ACHIEVES THE FOURTH MILESTONE OF ITS TRASTUZUMAB BIOSIMILAR LICENSING AGREEMENT
2021-07-21
Acepodia Publishes Preclinical Data on Novel Off-the-Shelf Natural Killer Cell Therapy, ACE1702, for HER2-Expressing Solid Tumors Using Antibody-Cell Conjugation Technology in the Journal Cancers
2021-06-07
Arthrosi Therapeutics, Inc. Announces Impressive Phase 2a Study Results for Gout Patients
2021-06-01
Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
2021-05-19
The Return of Jimmy Lai | Jimmy Lai, CFO, Acepodia
2021-05-19
Acepodia Presents Data on its Allogeneic Natural Killer-Like Gamma-Delta T Cell Therapy, ACE1831, in Development for Hematological Cancers
2021-05-19
ACT Genomics signs MOU with HKU SPACE on Training Healthcare Professionals in the Field of Genomics and Molecular Technology
2021-05-13
Acepodia Appoints Thorsten Graef, M.D., Ph.D., as Chief Medical Officer and Michael Brock as Chief Strategy Officer
2021-05-11
Arthrosi’s New Molecule AR882 for Gout Shows Blockbuster-Potential
2021-05-10
Advaxis to Present at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
2021-04-28
GenScript Launches Research-Grade Lentiviral Vector Packaging Service
2021-04-28
Advaxis Announces Receipt of Second Milestone Payment Under ADXS-HER2 Licensing Agreement with OS Therapies
2021-04-26
Advaxis, Inc. Announces $20 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2021-04-12
GenScript, Parkway Laboratories and Diagnostics Development (DxD) Hub collaborate to provide cPass™ SARS-CoV-2 Neutralizing Antibody Testing Service in Singapore
2021-04-12
Advaxis Presents Translational Biomarker Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the American Associated for Cancer Research (AACR) 2021 Annual Meeting
2021-04-10
HONG HAI/FOXCONN FOUNDER TERRY GUO ANNOUNCES INVESTMENT TO ACCELERATE EIRGENIX’S GLOBAL EXPANSION
2021-04-06
Advaxis Announces Agreement with Columbia University Irving Medical Center to Fund Phase 1 Study of ADXS-504 for the Treatment of Early Prostate Cancer
2021-04-05
Foresee Pharmaceuticals Announces Dosing of First Patient in Phase 2/3 Clinical Trial of FP-025 for Treatment of COVID-19 Associated ARDS
2021-03-28
US FDA Approves SyneuRx’s IND Application for PhaseΠ Clinical Trial for Adult Patients with Treatment-Resistant Depression and Suicidal Symptoms
2021-03-26
POSITIVE PHASE III CLINICAL RESULTS FOR EIRGENIX’S PROPOSED TRASTUZUMAB BIOSIMILAR
2021-03-23
Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells
2021-03-16
Advaxis to Present at the American Association for Cancer Research (AACR) 2021 Annual Meeting
2021-03-12
TFDA Approves SyneuRx to Conduct Phasa Πb/Ш Clinical Trials for its Drug Candidates Treating Schizophrenia
2021-03-08
Polaris Phase III interim analysis of lung mesothelioma carcinoma showed a statistically significant overall survival rate of 80% or higher for the highest grade.
2021-03-04
Foresee Pharmaceuticals Enters Exclusive License Agreement with Intas Pharmaceuticals for Commercialization in the United States
2021-03-04
Ω-NaBen, the Ultimate and Supreme Sodium Benzoate
2021-02-26
$2,000-Per-Dose Cell Therapy In The Clinic
2021-02-12
A novel endogenous CD16-Expressing Natural Killer Cell for cancer immunotherapy
2021-02-03
Advaxis Reports Fiscal Year 2020 Financial Results and Provides a Business Update
2021-01-25
Advaxis Announces Receipt of Funding Milestone Payment Under ADXS-HER2 Licensing Agreement with OS Therapies
2021-01-19
Acepodia’s Approach To ACC & CAR Manufacturing Scalability
2021-01-19
Taiwan Healthcare Data Preservation Platform Initiative
2021-01-15
Biopharma Executive Perspectives on 2021
2021-01-11
Foresee Pharmaceuticals Announces Completion of US$47 Million Financing
2020-12-24
SUMMIT study provided another treatment options for NSCLC EGFR exon 18 mutations patients
2020-12-22
Novel Resistance Mechanism for Savolitinib in MET-Amplified Gastric Cancer
2020-12-22
Clinical trial results of tazemetostat for INI1/SMARCB1-negative epithelioid sarcoma
2020-12-22
Advaxis Announces Listing Transfer to Nasdaq Capital Market and Additional 180-day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
2020-12-22
EIRGENIX AT 2020 HEALTHCARE+ EXPO TAIWAN – DECEMBER 3-6, 2020
2020-12-03
Advaxis, Inc. Announces Closing of $9.2 Million Public Offering
2020-11-27
Advaxis, Inc. Announces Pricing of $8 Million Public Offering
2020-11-24
CH5126766 is a novel potential treatment for RAS/RAF mutant cancers
2020-11-20
Adagrasib (MRTX849) showed efficacy and safety in KRASG12C NSCLCs from KRYSTAL-1 study
2020-11-20
A new oral SERD drug, SAR439859, shown the anti-tumor activity in ER+/Her2- breast cancer
2020-11-20
Foresee Pharmaceuticals Enters Exclusive License Agreement with GenSci for the Commercialization of Camcevi in China
2020-11-17
Acepodia to Present Late-breaking Poster Presentation Supporting the Potential of its NK Cell Therapy in Solid Tumors at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting
2020-11-09
Arthrosi Therapeutics Released Phase 2 Clinical Data of AR882
2020-11-09
Advaxis Presents Updated Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
2020-11-09
EIRGENIX COMPLETES NEOADJUVANT TREATMENT AND SURGERY FOR LAST PATIENT IN PHASE III CLINICAL TRIAL
2020-11-08
GenScript Receives FDA Emergency Use Authorization for World’s First SARS-CoV-2 Neutralizing Antibody Detection Kit
2020-11-06
Acepodia to Deliver Late-breaking Poster Presentation at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting
2020-11-02
Advaxis’ ADXS-503 (HOT Lung) Demonstrates Pronounced and Sustained Tumor Control in Ongoing Phase 1/2 Lung Cancer Trial
2020-10-26
An EGFR-MET bispecific antibody-Amivantamab(JNJ-372) combine with 3rd generation EGFR TKI-Lazertinib demonstrated safety and efficacy in a phase I trial
2020-10-22
Poziotinib showed potential in treating NSCLC patients harboring an ERBB2 Exon 20 insertion
2020-10-22
The biomarker exploratory analyzed results of the phase 3 JAVELIN Bladder 100 trial
2020-10-22
Acepodia to Present at the 7th Annual China Healthcare Summit
2020-10-22
Foresee Pharmaceuticals Announces NDA for CAMCEVI™ 42MG Accepted for Review by the FDA
2020-10-09
Polaris Group signs collaboration agreement with Nanotein Technologies, Inc.
2020-10-06
Advaxis, Inc. Adopts Limited Duration Stockholder Rights Plan
2020-09-29
VSTRIP® COVID-19 ANTIGEN RAPID TEST VALIDATED AND APPROVED IN INDIA!
2020-09-26
About
Team
Portfolio
News
Contact